Both retatrutide and tirzepatide represent significant advances in metabolic disorder treatment, but their mechanisms of action and initial clinical findings present key distinctions. Retatrutide functions as a dual GIP and GLP-1 target agonist, while tirzepatide also acts on both receptors. Earl